格瑞特生物技术在2025年ASGCT年会上展示多项科学突破-动脉网

Grit Biotechnology Presents Multiple Scientific Breakthroughs at ASGCT 2025 Annual Meeting

CISION 等信源发布 2025-05-12 20:30



可切换为仅中文







SHANGHAI

上海

，

May 12, 2025

2025年5月12日

/PRNewswire/ -- Grit Biotechnology Co., Ltd. ('

/PRNewswire/ -- 格里特生物技术有限公司（'

Grit Bio

坚韧生物

'), a clinical-stage biotech pioneering novel immunotherapies announced today that three research programs, in collaboration with Vitalgen BioPharma Co., Ltd. ('Vitalgen'), will be showcased in one oral presentation and two poster sessions at the American Society of Gene and Cell Therapy (ASGCT) 28

“），一家临床阶段的生物技术公司，开拓创新的免疫疗法，今天宣布与维泰尔根生物制药有限公司（‘维泰尔根’）合作的三个研究项目将在美国基因与细胞治疗学会 (ASGCT) 第28次会议上通过一次口头报告和两个海报展示呈现。”

annual meeting in

年度会议在

New Orleans, LA

路易斯安那州新奥尔良市

from

来自

May 13

5月13日

to 17

至17

。

Grit Bio

坚韧生物

will provide the updates of three preclinical programs, including APC-targeted neoantigen cancer vaccine, non-viral-nanoparticle-directed in vivo CAR-T, and LNP-mediated gene editing in tumor infiltrating lymphocyte (TIL). The details of three presentations are:

将提供三个临床前项目的更新，包括靶向APC的新抗原癌症疫苗、非病毒纳米颗粒引导的体内CAR-T以及LNP介导的肿瘤浸润淋巴细胞（TIL）基因编辑。三场报告的详情如下：

Title: APC-Targeted LNP Enables Systemic Delivery of Neoantigen mRNA Vaccines and Enhanced Antigen-Specific T Cell Responses

标题：靶向APC的LNP实现新抗原mRNA疫苗的系统递送及增强的抗原特异性T细胞反应

Presentation Type: Oral

报告类型：口头报告

Time:

时间：

5:15-5:30 pm

下午5:15-5:30

local time,

本地时间，

Thursday, May 15th

5月15日，星期四

Speaker: Pin Wang, Ph.D., CSO of Grit Biotechnology

演讲者：王品博士，Grit生物技术公司首席科学官

Title: In Vivo CAR-T Therapy Powered by Novel CLAMP Technology for T cell-Targeted mRNA Delivery

标题：利用新型CLAMP技术进行T细胞靶向mRNA递送的体内CAR-T疗法

Presentation Type: Poster

展示类型：海报

Time:

时间：

5:30-7:00 pm

下午5:30-7:00

local time,

本地时间，

Wednesday, May 14th

5月14日，星期三

Poster #: 1282

海报编号：1282

Title: Enhancing Production and Functional Potential of Tumor-Infiltrating Lymphocytes via Lipid Nanoparticle-Mediated CRISPR/Cas9 Gene Editing

标题：通过脂质纳米颗粒介导的CRISPR/Cas9基因编辑增强肿瘤浸润淋巴细胞的生产及功能潜力

Presentation Type: Poster

展示类型：海报

Time:

时间：

5:30-7:00 pm

下午5:30-7:00

local time,

本地时间，

Thursday, May 15th

5月15日，星期四

Poster #: 1776

海报编号：1776

'Through a strategic collaboration with Vitalgen, we are pioneering next-generation immunotherapies and precision delivery technologies. This synergy accelerates the development of advanced therapies with transformative improvements in safety and efficacy. We are now expanding those innovations toward global clinical implementation.' said Dr.

“通过与Vitalgen的战略合作，我们正在开创下一代免疫疗法和精准递送技术。这种协同作用加速了先进疗法的开发，并在安全性和有效性方面带来了变革性的提升。我们现在正将这些创新扩展到全球临床应用。”博士说道。

Yarong Liu, founder and Chief Executive Officer of Grit Biotechnology..

刘雅蓉，格瑞特生物技术公司的创始人兼首席执行官。

About

关于

Grit Bio

坚韧生物

GRIT Bio was founded in 2019 as an innovative biopharmaceutical company, focused on immune cell treatments for oncology and characterized by a R&D pipeline in TIL therapies. GRIT Bio has completed multiple rounds of equity financing and is backed by renowned venture capital funds. GT101, a proprietary injectable developed by GRIT Bio, is the first TIL therapy that entered registrational clinical trial.

GRIT Bio成立于2019年，是一家创新型生物制药公司，专注于肿瘤免疫细胞治疗，以TIL疗法的研发管线为特色。GRIT Bio已完成多轮股权融资，得到知名风险投资基金的支持。其自主研发的注射用GT101是首个进入注册性临床试验的TIL疗法。

GT 101 is currently in pivotal Phase II clinical study. GRIT Bio's GT201 injectable, the first TIL therapy with membrane-bound IL-15 complex, has cleared IND in both US and .

GT 101目前处于关键的II期临床研究阶段。GRIT Bio的GT201注射剂是首个带有膜结合IL-15复合物的TIL疗法，已在美国和中国获得IND批准。

China

中国

. Core R&D platforms of the company include StemTexp

公司的核心研发平台包括StemTexp

stemness TIL expansion platform, StaViral

干细胞样TIL扩展平台，StaViral

stably virus transfected cell lines, ImmuT Finder

稳定病毒转染的细胞系，ImmuT Finder

immune modulator target discovery platform, and KOReTIL

免疫调节剂靶点发现平台，以及KOReTIL

high-efficiency gene knock-out system. Based on the platforms, GRIT Bio generated a series of next-generation gene-edited TIL therapies. With internationally advanced technology reserve and industry resources, GRIT Bio aims to develop breakthrough therapies for solid tumors and bring new hope to cancer patients.

高效的基因敲除系统。基于这些平台，GRIT生物生成了一系列下一代基因编辑的TIL疗法。凭借国际先进的技术储备和行业资源，GRIT生物旨在开发针对实体瘤的突破性疗法，为癌症患者带来新的希望。

For further information, please visit: .

如需更多信息，请访问：。

www.grit-bio.com

About Vitalgen

关于Vitalgen

Vitalgen BioPharma Co., Ltd. is a patient-focused, innovation-driven biotechnology company developing transformative gene therapies. With vertically integrated proprietary platforms, Vitalgen focuses on rare and common diseases while enabling partners to leverage its technologies across multiple therapeutic areas.

Vitalgen BioPharma Co., Ltd. 是一家以患者为中心、创新驱动的生物技术公司，致力于开发变革性的基因疗法。通过垂直整合的专有平台，Vitalgen 专注于罕见病和常见病，同时助力合作伙伴在多个治疗领域利用其技术。

Founded in 2020 and headquartered in .

成立于2020年，总部位于。

Shanghai, China

中国上海

, Vitalgen operates state-of-the-art facilities compliant with both China GMP and US cGMP standards. For more information, visit

，Vitalgen运营着符合中国GMP和美国cGMP标准的最先进的设施。欲了解更多信息，请访问

www.vitalgen.com

。

Forward-Looking Statements

前瞻性声明

This press release contains forward-looking statements about Grit Biotechnology based on management's current expectations, which are subject to known and unknown uncertainties and risks. Words such as 'anticipated,' 'expect,' 'intend,' 'plan,' 'believe,' 'seek,' 'estimate,' 'may,' 'will,' and variations of these words or similar expressions are intended to identify forward-looking statements.

本新闻稿包含基于管理层当前预期的关于坚毅生物技术公司的前瞻性声明，这些声明受已知和未知的不确定性和风险影响。诸如“预期”、“预计”、“打算”、“计划”、“相信”、“寻求”、“估计”、“可能”、“将”等词语或这些词语的变体或类似表述旨在识别前瞻性声明。

These forward-looking statements include statements regarding our expectations for our technology platforms, gene therapy candidates in development, collaborations, and plans for commercialization. Our actual results could differ materially from those discussed due to a number of factors, including, but not limited to, the risk inherent in developing pharmaceutical product candidates, conducting successful clinical trials, and obtaining regulatory approvals.

这些前瞻性声明包括关于我们技术平台的预期、正在开发的基因治疗候选产品、合作以及商业化计划的声明。由于多种因素，包括但不限于开发药物候选产品、进行成功的临床试验以及获得监管批准的风险，我们的实际结果可能会与讨论的内容有重大差异。

Except as required by law, Grit Biotechnology assumes no obligation to update any forward-looking statements contained herein as a result of new information, future events, or otherwise..

除非法律要求，格里特生物技术公司不承担因新信息、未来事件或其他原因而更新本文中包含的任何前瞻性陈述的义务。

SOURCE Grit Biotechnology

来源：Grit生物技术

WANT YOUR COMPANY'S NEWS

想要你公司的新闻

FEATURED ON PRNEWSWIRE.COM?

荣登PRNEWSWIRE.COM？

440k+

44万+

Newsrooms &

新闻编辑室 &

Influencers